+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Premenstrual Syndrome Treatment Market - Global Forecast 2026-2032- Product Image
Premenstrual Syndrome Treatment Market - Global Forecast 2026-2032- Product Image
New

Premenstrual Syndrome Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5967666
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The premenstrual syndrome treatment market is advancing steadily, influenced by clinical innovations, digital health integration, and shifting regulatory standards. Senior leaders can use this targeted overview to inform strategic planning and respond effectively to evolving care delivery and supply chain paradigms within this complex therapeutic space.

Market Snapshot: Premenstrual Syndrome Treatment Market

The global premenstrual syndrome treatment market is on a trajectory of moderate, sustained growth. Expanding from USD 1.87 billion in 2025 to USD 1.96 billion in 2026 and projected to reach USD 2.65 billion by 2032, the primary driver is the combined uptake of pharmacological and nonpharmacological therapies. A compound annual growth rate of 5.05% underscores the sector’s resilience, shaped by digital platform integration and increasing regulatory engagement. This market is responding to broadening clinical requirements, innovative treatment approaches, and diversified distribution frameworks across geographies.

Scope & Segmentation

This report provides an in-depth analysis of the evolving landscape in premenstrual syndrome treatment, giving senior decision-makers clear insight into market drivers and adoption patterns across care settings and geographies. The following key segmentation factors inform actionable strategies:

  • Treatment Types: This encompasses both nonpharmacological approaches, such as cognitive behavioral therapy and digital therapeutics, as well as core pharmacological interventions including combined oral contraceptives, GABA analogs, and selective serotonin reuptake inhibitors. Lifestyle management and targeted nutritional supplements offer additional modalities, shaping patient-centric strategies.
  • End User Settings: Hospital environments, specialty clinics, and home care settings are all highlighted, as each influences intervention uptake, reimbursement pathways, and levels of patient engagement. The interplay among these settings guides market adoption and service delivery models.
  • Product Forms: The availability of capsules, oral liquids, and tablets directly impacts patient acceptability, adherence, manufacturing complexity, and the efficiency of distribution networks. These forms provide flexibility for both providers and end users.
  • Regional Coverage: Evaluation spans the Americas, Europe, Middle East & Africa, and Asia-Pacific. The report details pertinent regulatory requirements, evidence standards, and distinct distribution models present in each region, assisting in the identification of entry barriers and localization opportunities.
  • Technologies & Innovations: Digital therapeutics, telehealth, integrated care pathways, and precision nutrition technology are being increasingly adopted. The focus is on enabling tailored interventions and supporting integrated, data-driven care for optimized therapeutic impact.

Key Takeaways for Senior Decision-Makers

  • Across global supply chains, suppliers are accelerating diversification of sourcing to address emerging tariff regimes and complex compliance landscapes.
  • Integration of nonpharmacological methods alongside traditional pharmacology is enabling patient-centered models, enhancing the effectiveness and personalization of care pathways with digital tools.
  • Cross-sector partnerships between pharmaceutical, supplement, and digital health organizations are shifting commercial strategies, promoting distinct product positioning and seamless health service integration.
  • Consensus-building around high-quality evidence generation is essential, not only to reinforce product claims but also to streamline reimbursement and promote clinical uptake across markets with varying regulatory expectations.
  • Regional heterogeneity in regulatory processes, education, and distribution requires organizations to deploy localised market access and partnership strategies for successful product registration and sustained adoption.

Tariff Impact Across Global Supply Chains

Recent tariff changes in the United States have prompted shifts in sourcing and manufacturing for both pharmaceutical and supplement suppliers. To address single-region dependency, companies are enhancing inventory management and adopting vertical integration. This transition is influencing choice of product formulations and encourages collaboration throughout the value chain. As a result, flexible formularies and alternative therapy choices are prioritized, supporting access and continuity of care while reducing operational and regulatory risk exposure.

Methodology & Data Sources

The report’s analysis employs a rigorous synthesis of peer-reviewed clinical research, contemporary regulatory guidance, and authoritative sector reports. Findings are underpinned by primary interviews with experts in clinical, commercial, and supply chain domains and quantitative review of anonymized claims and procurement datasets. Systematic triangulation and context-driven validation measures further ensure reliable insights.

Why This Report Matters

  • Presents benchmarks supporting robust evidence generation for innovative therapies and more defensible clinical claims in the premenstrual syndrome treatment market.
  • Reveals tactical options for supply chain resilience, improved regulatory engagement, and operational risk reduction for market participants.
  • Highlights current patterns of adoption in care delivery, technology use, and regional deployment to support design and expansion of patient-focused solutions.

Conclusion

This strategic analysis empowers organizations to optimize care delivery, strengthen supply chain endurance, and maintain differentiated market positioning. Collaborative evidence generation and pragmatic engagement with evolving standards are central to harnessing new opportunities and advancing patient outcomes in premenstrual syndrome treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Premenstrual Syndrome Treatment Market, by Treatment Type
8.1. Non Pharmacological Treatment
8.1.1. Cognitive Behavioral Therapy
8.1.2. Lifestyle Management
8.1.3. Nutritional Supplements
8.1.3.1. Amino Acid Derivatives
8.1.3.2. Herbal Extracts
8.1.3.3. Vitamins & Minerals
8.2. Pharmacological Treatment
9. Premenstrual Syndrome Treatment Market, by Product Form
9.1. Capsule
9.2. Oral Liquid
9.3. Tablet
10. Premenstrual Syndrome Treatment Market, by End User
10.1. Home Care Settings
10.2. Hospitals
10.3. Specialty Clinics
11. Premenstrual Syndrome Treatment Market, by Region
11.1. Americas
11.1.1. North America
11.1.2. Latin America
11.2. Europe, Middle East & Africa
11.2.1. Europe
11.2.2. Middle East
11.2.3. Africa
11.3. Asia-Pacific
12. Premenstrual Syndrome Treatment Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Premenstrual Syndrome Treatment Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. United States Premenstrual Syndrome Treatment Market
15. China Premenstrual Syndrome Treatment Market
16. Competitive Landscape
16.1. Market Concentration Analysis, 2025
16.1.1. Concentration Ratio (CR)
16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025
16.5. Bayer AG
16.6. Eli Lilly and Company
16.7. GlaxoSmithKline plc
16.8. Johnson & Johnson Services, Inc.
16.9. Novartis AG
16.10. Pfizer Inc.
16.11. Sanofi S.A.
16.12. Sun Pharmaceutical Industries Ltd.
16.13. Teva Pharmaceutical Industries Ltd.
16.14. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 11. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 51. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 53. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 54. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 55. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 56. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 59. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 60. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 61. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 64. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 65. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 66. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 67. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 71. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 74. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 76. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 77. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 78. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 79. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 83. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 84. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 85. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 88. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 89. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 90. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 91. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 101. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 102. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 103. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 104. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 107. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 108. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 109. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 110. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 113. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 114. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 115. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 116. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 119. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 120. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 121. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 122. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 125. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 126. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 127. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 128. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 131. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 132. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 133. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 134. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 137. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 138. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 139. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 140. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 141. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 143. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 144. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
TABLE 145. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
TABLE 146. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
TABLE 147. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Premenstrual Syndrome Treatment market report include:
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.96 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.65 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2025-2033 - Product Image

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2025-2033

  • Report
  • 148 Pages
  • Global
From
Premenstrual Syndrome Treatment Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Premenstrual Syndrome Treatment Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Premenstrual Syndrome Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Premenstrual Syndrome Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, Countries and Company Analysis 2025-2033 - Product Image

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, Countries and Company Analysis 2025-2033

  • Report
  • 200 Pages
  • Global
From
Premenstrual Syndrome and Menstrual Health Supplements - Global Strategic Business Report - Product Image

Premenstrual Syndrome and Menstrual Health Supplements - Global Strategic Business Report

  • Report
  • 463 Pages
  • Global
From

About the Premenstrual Syndrome Drug Market

The Premenstrual Syndrome (PMS) Drug market is a subset of the Sexual and Reproductive Health Drugs market. PMS drugs are used to treat the physical and psychological symptoms associated with premenstrual syndrome, such as mood swings, irritability, bloating, and breast tenderness. These drugs are typically taken orally, and may include hormonal contraceptives, non-steroidal anti-inflammatory drugs, and selective serotonin reuptake inhibitors. The PMS Drug market is driven by the increasing prevalence of premenstrual syndrome, as well as the growing awareness of the condition and its associated symptoms. Additionally, the availability of generic drugs and the increasing demand for over-the-counter medications are expected to drive the market. Some companies in the PMS Drug market include Bayer AG, Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, and Eli Lilly and Company. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.